About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Investigational New Drugs
›
Top Articles
Investigational New Drugs
Oncology
,
Pharmacology
4.3
(top 3%)
Impact Factor
4.5
(top 3%)
extended IF
91
(top 4%)
H-Index
2.1K
authors
3.4K
papers
69.5K
citations
4.2K
citing journals
40.3K
citing authors
Most Cited Articles of Investigational New Drugs
Title
Year
Citations
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
1992
517
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
2017
498
Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic
1999
421
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
1994
373
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
2005
346
Matrix metalloproteinase inhibitors
1997
327
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
2014
323
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development
2000
265
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
2015
260
Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity
1999
245
Role of formulation vehicles in taxane pharmacology
2001
240
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
2011
230
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
2011
229
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
2014
226
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
2013
220
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
2007
215
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials
1999
206
Proteasome inhibition: a new strategy in cancer treatment
2000
197
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
2012
193
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
2008
192
Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results
1999
178
Aurora kinase inhibitors: progress towards the clinic
2012
176
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
2013
172
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
2012
164
Development of artemisinin compounds for cancer treatment
2013
157
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.